Leitlinien, Literatur und Fachgesellschaften

Leitlinien internationaler Fachgesellschaften

ENETS Guidelines

ENETS - Consensus Report 2025

Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European NeuroendocrineTumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force. Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, Christ E, Lamarca A, Caplin M, Castaño JP, Dromain C, Falconi M, Grozinsky-Glasberg S, Hofland J, Knigge UP, Kos-Kudla B, Krishna BA, Reed NS, Scarpa A, Srirajaskanthan R, Toumpanakis C, Kjaer A, Hicks RJ, Ambrosini V. J Neuroendocrinol. 2025 Feb;37(2):e13479. doi: 10.1111/jne.13479. Epub 2024 Dec 9. PMID: 39653582

ENETS - Guidance Paper 2024

European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, Rinke A, Janson ET, Thirlwell C, van Velthuysen MF, Vullierme MP, Pavel M. J Neuroendocrinol. 2024 Jul 8:e13423. doi: 10.1111/jne.13423. Epub ahead of print. PMID: 38977327
Use and perceived utility of [(18) F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. J Neuroendocrinol. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. PMID: 38097193

ENETS - Guidance Paper 2023

European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. Kos-Kudła B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumarianou A, de Mestier L, Partelli S, Perren A, Stättner S, Valle JW, Fazio N.J Neuroendocrinol. 2023 Oct 5:e13343. doi: 10.1111/jne.13343. Online ahead of print. PMID: 37877341
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J, Begum N, Sundin A, Falconi M, O'Toole D. J Neuroendocrinol. 2023 Aug;35(8):e13306. doi: 10.1111/jne.13306. Epub 2023 Jul 4. PMID: 37401795
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111/jne.13318. Epub 2023 Aug 14. PMID: 37578384
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). Kaltsas G, Walter T, Knigge U, Toumpanakis C, Santos AP, Begum N, Pape UF, Volante M, Frilling A, Couvelard A. J Neuroendocrinol. 2023 Aug 16. doi: 10.1111/jne.13332. Epub ahead of print. PMID: 37682701
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, van Dijkum EN, O'Toole D, Rindi G, Scoazec JY, Ramage J. J Neuroendocrinol. 2023 Jun;35(6):e13309. doi: 10.1111/jne.13309. Epub 2023 Jun 22. PMID: 37345509
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, Knigge U, Christ E, Ambrosini V, Couvelard A, Tiensuu Janson E. J Neuroendocrinol. 2023 Mar;35(3):e13249. doi: 10.1111/jne.13249. Epub 2023 Mar 16. PMID: 36924180

ENETS-Empfehlungen – Standardized Synoptic Reporting 2021/2022

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Albåge A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111/jne.13146. Epub 2022 May 25. PMID: 35613326; PMCID: PMC9539661
ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology. van Velthuysen MF, Couvelard A, Rindi G, Fazio N, Hörsch D, Nieveen van Dijkum EJ, Klöppel G, Perren A. J Neuroendocrinol. 2022 Mar;34(3):e13100. doi: 10.1111/jne.13100. Epub 2022 Feb 14. PMID: 35165954; PMCID: PMC9285411
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). J Neuroendocrinol. 2022 Mar;34(3):e13105. doi: 10.1111/jne.13105. Epub 2022 Mar 1. PMID: 35233848
ENETS standardized (synoptic) reporting in neuroendocrine tumours. de Herder WW, Fazio N, O'Toole D. J Neuroendocrinol. 2022 Mar;34(3):e13054. doi: 10.1111/jne.13054. Epub 2021 Nov 5. PMID: 34739148
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. J Neuroendocrinol. 2022 Mar;34(3):e13044. doi: 10.1111/jne.13044. Epub 2021 Oct 25. PMID: 34693574; PMCID: PMC9286653
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. J Neuroendocrinol. 2022 Mar;34(3):e13040. doi: 10.1111/jne.13040. Epub 2021 Oct 20. PMID: 34668262
Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force). Hofland J, Lamarca A, Steeds R, Toumpanakis C, Srirajaskanthan R, Riechelmann R, Panzuto F, Frilling A, Denecke T, Christ E, Grozinsky-Glasberg S, Davar J; ENETS Carcinoid Heart Disease Task Force. J Neuroendocrinol. 2022 Mar;34(3):e13060. doi: 10.1111/jne.13060. Epub 2021 Nov 26. PMID: 34825753; PMCID: PMC9286034

ENETS - Standards of Care 2017

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):245-254. doi: 10.1159/000461583. Epub 2017 Mar 2. PMID: 28253514; PMCID: PMC5637287
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):255-265. doi: 10.1159/000464292. Epub 2017 Feb 25. PMID: 28237989
ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):310-319. doi: 10.1159/000458155. Epub 2017 Feb 17. PMID: 28222443
ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Pavel M, de Herder WW. Neuroendocrinology. 2017;105(3):193-195. doi: 10.1159/000457957. Epub 2017 Feb 11. PMID: 28190018
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):196-200. doi: 10.1159/000457956. Epub 2017 Feb 11. PMID: 28190015
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13. PMID: 28402980
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 8. PMID: 28391265
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):281-294. doi: 10.1159/000473892. Epub 2017 Apr 5. PMID: 28380493
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):212-244. doi: 10.1159/000471879. Epub 2017 Mar 30. PMID: 28355596
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference participants. Neuroendocrinology. 2017;105(3):266-280. doi: 10.1159/000471880. Epub 2017 Mar 29. PMID: 28351033

ENETS - Guidelines 2016

ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):144-52. doi: 10.1159/000443165. Epub 2016 Jan 5. PMID: 26730583
ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):139-43. doi: 10.1159/000443166. Epub 2016 Jan 5. PMID: 26730835
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5. PMID: 26731013
ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. O'Toole D, Kianmanesh R, Caplin M. Neuroendocrinology. 2016;103(2):117-8. doi: 10.1159/000443169. Epub 2016 Jan 6. PMID: 26731186
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5. PMID: 26742109; PMCID: PMC4849884
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5. PMID: 26731334
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. PMID: 25646366
ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):119-24. doi: 10.1159/000443168. Epub 2016 Jan 19. PMID: 26784901
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. Neuroendocrinology. 2016;103(2):125-38. doi: 10.1159/000443170. Epub 2016 Jan 12. PMID: 26758972

ESES Guidelines

2024

Surgery for advanced neuroendocrine tumours of the small bowel: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES). Van Den Heede K, van Beek DJ, Van Slycke S, Borel Rinkes I, Norlén O, Stålberg P, Nordenström E. Br J Surg. 2024 Apr 3;111(4):znae082. doi: 10.1093/bjs/znae082.PMID: 38626261
Surgery for advanced pancreatic neuroendocrine neoplasms: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES). Van Beek DJ, Van Den Heede K, Borel Rinkes I, Norlén O, Van Slycke S, Stålberg P, Nordenström E. Br J Surg. 2024 Jan 31;111(2):znae017. doi: 10.1093/bjs/znae017. PMID: 38364061

ESMO Guidelines

2024

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, Pavel M, Thariat J, van Velthuysen MF, Herman P, Dromain C, Baudin E, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2024 Oct;9(10):103664. doi: 10.1016/j.esmoop.2024.103664. Epub 2024 Oct 1. PMID: 39461777

2021

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Erratum in: Ann Oncol. 2021 Nov;32(11):1453-1455. PMID: 33482246

2020

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2020 Jul;31(7):844-860. doi: 10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6. PMID: 32272208

NCCN Guidelines

NCCN

NANETS Guidelines

2023

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Endocr Relat Cancer. 2023 Jul 11;30(8):e220206. doi: 10.1530/ERC-22-0206. PMID: 37184955; PMCID: PMC10388681

2020

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. Pancreas. 2020 Aug;49(7):863-881. doi: 10.1097/MPA.0000000000001597. PMID: 32675783
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. Pancreas. 2020 Jan;49(1):1-33. doi: 10.1097/MPA.0000000000001454. PMID: 31856076; PMCID: PMC7029300
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. Pancreas. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561. PMID: 32433264; PMCID: PMC7253037

2018

Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Chan DL, Moody L, Segelov E, Metz DC, Strosberg JR, Pavlakis N, Singh S. Neuroendocrinology. 2018;107(1):32-41. doi: 10.1159/000488394. Epub 2018 Mar 14. PMID: 29539613

2017

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. PMID: 28609357; PMCID: PMC5502737
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. PMID: 28609356; PMCID: PMC5642985

2013

Consensus guidelines for the management and treatment of neuroendocrine tumors. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Pancreas. 2013 May;42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4. PMID: 23591432; PMCID: PMC4304762
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f. PMID: 20664477; PMCID: PMC3100733
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):784-98. doi: 10.1097/MPA.0b013e3181ec1380. PMID: 20664476
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):775-83. doi: 10.1097/MPA.0b013e3181ebb4f0. PMID: 20664475; PMCID: PMC3419007
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):767-74. doi: 10.1097/MPA.0b013e3181ec1261. PMID: 20664474
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):753-66. doi: 10.1097/MPA.0b013e3181ebb2a5. PMID: 20664473
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):735-52. doi: 10.1097/MPA.0b013e3181ebb168. PMID: 20664472; PMCID: PMC3100728
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd. PMID: 20664471
The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Kvols LK, Brendtro KL; North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2010 Aug;39(6):705-6. doi: 10.1097/MPA.0b013e3181eb7451. PMID: 20664469

ASCO Guidelines

2025

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK. JCO Oncol Pract. 2025 May 9:OP2500133. doi: 10.1200/OP-25-00133. Online ahead of print. PMID: 40344544

2023

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK.J Clin Oncol. 2023 Sep 29:JCO2301529. doi: 10.1200/JCO.23.01529. Online ahead of print. PMID: 37774329
Leitlinien nationaler Fachgesellschaften

S2K-Leitlinie Neuroendokrine Tumoren – AWMF Leitlinienregister

2018

S2K-Leitlinie Neuroendokrine Tumoren - AWMF Leitlinienregister

Nordic Guidelines

2023

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Dam G, Grønbæk H, Sundlöv A, Botling J, Sundin A, Petersen RH, Welin S, Evensen ET, Sorbye H, Tabaksblat E, Arveschoug AK, Mortensen J, Kjaer A, Knigge U, Tiensuu Janson E, Langer SW. Acta Oncol. 2023 May;62(5):431-437. doi: 10.1080/0284186X.2023.2212411. Epub 2023 May 16. PMID: 37194281

2021

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, Langer SW, Kjaer A, Arola J, Schalin-Jäntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Acta Oncol. 2021 Jul;60(7):931-941. doi: 10.1080/0284186X.2021.1921262. Epub 2021 May 17. PMID: 33999752

2014

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20. PMID: 25140861

2010

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki MJ, Oberg K, Knigge U. Acta Oncol. 2010 Aug;49(6):740-56. doi: 10.3109/0284186X.2010.492791. PMID: 20553100

Spanish Guidelines

2022

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022). Castillón JC, Gordoa TA, Bayonas AC, Carretero AC, García-Carbonero R, Pulido EG, Fonseca PJ, Lete AL, Huerta AS, Plazas JG. Clin Transl Oncol. 2023 Sep;25(9):2692-2706. doi: 10.1007/s12094-023-03205-6. Epub 2023 May 19. PMID: 37204633; PMCID: PMC10425298

2018

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R. Clin Transl Oncol. 2019 Jan;21(1):55-63. doi: 10.1007/s12094-018-1980-7. Epub 2018 Dec 7. PMID: 30535553; PMCID: PMC6339660

2014

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I; Spanish Society for Medical Oncology. Clin Transl Oncol. 2014 Dec;16(12):1025-34. doi: 10.1007/s12094-014-1214-6. Epub 2014 Sep 3. PMID: 25183048; PMCID: PMC4239790

2011

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). García-Carbonero R, Salazar R, Sevilla I, Isla D. Clin Transl Oncol. 2011 Aug;13(8):545-51. doi: 10.1007/s12094-011-0695-9. PMID: 21821488

French Guidelines

2022

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022). Castillón JC, Gordoa TA, Bayonas AC, Carretero AC, García-Carbonero R, Pulido EG, Fonseca PJ, Lete AL, Huerta AS, Plazas JG. Clin Transl Oncol. 2023 Sep;25(9):2692-2706. doi: 10.1007/s12094-023-03205-6. Epub 2023 May 19. PMID: 37204633; PMCID: PMC10425298

2020

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Dig Liver Dis. 2020 May;52(5):473-492. doi: 10.1016/j.dld.2020.02.011. Epub 2020 Mar 28. PMID: 32234416

Italian Guidelines

2024

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Panzuto F, Albertelli M, De Rimini ML, Rizzo FM, Grana CM, Cives M, Faggiano A, Versari A, Tafuto S, Fazio N, Colao A, Scalorbi F, Ferone D, Cinieri S, Maccauro M. J Endocrinol Invest. 2024 Oct 12. doi: 10.1007/s40618-024-02448-6. Online ahead of print. PMID: 39395114 Review.

Australasian Guidelines

2022

Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wyld D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. Neuroendocrinology. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1. PMID: 36049462

Japanese Guidelines

2021

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. J Gastroenterol. 2021 Nov;56(11):1033-1044. doi: 10.1007/s00535-021-01827-7. Epub 2021 Sep 29. PMID: 34586495; PMCID: PMC8531106
Themenspezifische Literatur / Leitlinien / Reviews

Vergleich verschiedener Leitlinienempfehlungen

2024

Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors. Panzuto F, Lamarca A, Fazio N. Cancer Treat Rev. 2024 Sep;129:102803. doi: 10.1016/j.ctrv.2024.102803. Epub 2024 Jul 14. PMID: 39029154

Klassifikation und Staging (WHO, AICC, UICC)

2024

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. CA Cancer J Clin. 2024 Jul-Aug;74(4):359-367. doi: 10.3322/caac.21840. Epub 2024 Apr 29. PMID: 38685134
Diagnostic issues in neuroendocrine neoplasms of the lung. Kasajima A, Klöppel G. Pathologie (Heidelb). 2024 Oct 2. English. doi: 10.1007/s00292-024-01360-3. Epub ahead of print. PMID: 39356330
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours. Juhlin CC. J Clin Pathol. 2024 Jul 9:jcp-2023-209060. doi: 10.1136/jcp-2023-209060. Epub ahead of print. PMID: 38981664
Aktuelle WHO-Klassifikation (2022) neuroendokriner Neoplasien [Current WHO classification (2022) of neuroendocrine neoplasms]. Buchstab O, Knösel T. Radiologie (Heidelb). 2024 Jul;64(7):531-535. German. doi: 10.1007/s00117-024-01295-z. Epub 2024 Apr 15. PMID: 38622292
Changes in categorization or nomenclature within neuroendocrine tumors. Vocino Trucco G, Volante M. Endocr Relat Cancer. 2024 Jun 13;31(8):e240004. doi: 10.1530/ERC-24-0004. PMID: 38776393
Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. Mathian É, Drouet Y, Sexton-Oates A, Papotti MG, Pelosi G, Vignaud JM, Brcic L, Mansuet-Lupo A, Damiola F, Altun C, Berthet JP, Fournier CB, Brustugun OT, Centonze G, Chalabreysse L, de Montpréville VT, di Micco CM, Fadel E, Gadot N, Graziano P, Hofman P, Hofman V, Lacomme S, Lund-Iversen M, Mangiante L, Milione M, Muscarella LA, Perrin C, Planchard G, Popper H, Rousseau N, Roz L, Sabella G, Tabone-Eglinger S, Voegele C, Volante M, Walter T, Dingemans AM, Moonen L, Speel EJ, Derks J, Girard N, Chen L, Alcala N, Fernandez-Cuesta L, Lantuejoul S, Foll M. ESMO Open. 2024 Jun;9(6):103591. doi: 10.1016/j.esmoop.2024.103591. Epub 2024 Jun 14. PMID: 38878324
Expanding Role of Gastroenterology in the Staging of Digestive Neuroendocrine Tumors: Updates From the American Joint Committee on Cancer Version 9 Cancer Staging System. Ge PS, Shi C, Asare E, Washington MK, O'Toole D; American Joint Committee on Cancer Expert Panel on Neuroendocrine Tumors. Clin Gastroenterol Hepatol. 2024 Mar;22(3):448-451. doi: 10.1016/j.cgh.2023.10.033. Epub 2023 Dec 5. PMID: 38056801
Updates on lung neuroendocrine neoplasm classification. Vocino Trucco G, Righi L, Volante M, Papotti M. Histopathology. 2024 Jan;84(1):67-85. doi: 10.1111/his.15058. Epub 2023 Oct 4. PMID: 37794655

2022

Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L. Endocr Pathol. 2022 Mar;33(1):197-227. doi: 10.1007/s12022-022-09705-5. Epub 2022 Mar 13. PMID: 35285003
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Endocr Pathol. 2022 Mar;33(1):115-154. doi: 10.1007/s12022-022-09708-2. Epub 2022 Mar 16. PMID: 35294740
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20. PMID: 34808341

NET G3 und NEC

2025

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, Janson ET, Garresori H, Hofsli E, Kersten C, Elvebakken H, Pfeiffer P, Morken S, Assmus J, Lothe IMB, Tabaksblat E, Knigge U, Couvelard A, Perren A, Langer SW. Br J Cancer. 2025 May 17. doi: 10.1038/s41416-025-03054-w. Online ahead of print. PMID: 40382522

2024

PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J. J Neuroendocrinol. 2025 Mar;37(3):e13443. doi: 10.1111/jne.13443. Epub 2024 Sep 7. PMID: 39243213

Klinische Phase 3 Studienergebnisse in NENs

Somatostatinanaloga

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrinetumours: final results of the CLARINET open-label extension study. Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P; CLARINET Investigators. Endocrine. 2021 Feb;71(2):502-513. doi: 10.1007/s12020-020-02475-2. Epub 2020 Oct 14. PMID: 33052555
Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial. Rinke A, Neary MP, Eriksson J, Hunger M, Doan T, Karli D, Arnold R. Neuroendocrinology. 2019;109(2):141-151. doi: 10.1159/000499469. Epub 2019 Mar 11. PMID: 30852564
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group. Neuroendocrinology. 2017;104(1):26-32. doi: 10.1159/000443612. Epub 2016 Jan 6. PMID: 26731483
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrinetumours: the CLARINET open-label extension study. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490. Epub 2016 Jan 7. PMID: 26743120
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. PMID: 25014687
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. PMID: 19704057

Telotristat

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. Neuroendocrinology. 2022;112(3):298-310. doi: 10.1159/000516958. Epub 2021 May 3. PMID: 33940581
Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Clin Ther. 2021 Oct;43(10):1779-1785. doi: 10.1016/j.clinthera.2021.08.014. Epub 2021 Sep 28. PMID: 34598813
Time to Sustained Improvement in Bowel Movement Frequency with TelotristatEthyl: Analyses of Phase III Studies in Carcinoid Syndrome. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. J Gastrointest Cancer. 2021 Mar;52(1):212-221. doi: 10.1007/s12029-020-00375-2. PMID: 32146619
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECASTphase 3 trial. Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12. PMID: 29330194
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. J Clin Oncol. 2017 Jan;35(1):14-23. doi: 10.1200/JCO.2016.69.2780. Epub 2016 Oct 28. PMID: 27918724

177Lu-DOTA-TATE

[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203
(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7. PMID: 29878866
Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709

Everolimus

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Ann Oncol. 2019 Dec 1;30(12):2010. doi: 10.1093/annonc/mdz222. PMID: 31406974
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193. PMID: 28444114
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K. J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30. PMID: 27621394
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. PMID: 26703889
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. PMID: 22119496
Everolimus for advanced pancreatic neuroendocrine tumors. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. PMID: 21306238

Sunitinib

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E. Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561. PMID: 27836885
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. PMID: 21306237

Cabozantinib

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. N Engl J Med. 2024 Sep 16. doi: 10.1056/NEJMoa2403991. Online ahead of print. PMID: 39282913

Surufatinib

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20. PMID: 32966811
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Lancet Oncol. 2020 Nov;21(11):1489-1499. doi: 10.1016/S1470-2045(20)30493-9. Epub 2020 Sep 20. PMID: 32966810

Bevacizumab

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS.J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6. PMID: 28384065

PDQ^® Cancer Information for Health Professionals, National Cancer Institute

2024

Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version. PDQ Adult Treatment Editorial Board. 2024 Sep 19. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389233
Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version. PDQ Pediatric Treatment Editorial Board. 2024 Sep 13. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 31661208
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version. PDQ Adult Treatment Editorial Board. 2024 Aug 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389309
Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version. PDQ Cancer Genetics Editorial Board. 2024 Jun 12. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389271

PDQ^® Cancer Information for Patients, National Cancer Institute

2023

Gastrointestinal Neuroendocrine Tumors Treatment (PDQ): Patient Version. PDQ Adult Treatment Editorial Board. 2023 Jun 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389212

2022

Childhood Gastrointestinal Neuroendocrine Tumors Treatment (PDQ): Patient Version. PDQ Pediatric Treatment Editorial Board. 2022 Dec 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 31661205
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ): Patient Version. PDQ Adult Treatment Editorial Board. 2022 Oct 7. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389340

European Society for Hybrid, Molecular and Translational Imaging

2024

ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. Eur Radiol. 2024 Oct 10. doi: 10.1007/s00330-024-11095-7. Online ahead of print. PMID: 39387873

Pankreaschirurgie

2024

Clinical Practice Guideline: Recommendations for the Perioperative Management of Pancreatic and Colorectal Cancer Patients. Vilz TO, Post S, Langer T, Follmann M, Nothacker M, Willis MA; the POMGAT Guideline Group. Dtsch Arztebl Int. 2024 Oct 4;(Forthcoming):arztebl.m2024.0172. doi: 10.3238/arztebl.m2024.0172. Online ahead of print. PMID: 39189068
Surgery for advanced pancreatic neuroendocrine neoplasms: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES). Van Beek DJ, Van Den Heede K, Borel Rinkes I, Norlén O, Van Slycke S, Stålberg P, Nordenström E. Br J Surg. 2024 Jan 31;111(2):znae017. doi: 10.1093/bjs/znae017. PMID: 38364061
International consensus guidelines on robotic pancreatic surgery in 2023. Liu R, Abu Hilal M, Besselink MG, Hackert T, Palanivelu C, Zhao Y, He J, Boggi U, Jang JY, Panaro F, Goh BKP, Efanov M, Nagakawa Y, Kim HJ, Yin X, Zhao Z, Shyr YM, Iyer S, Kakiashvili E, Han HS, Lee JH, Croner R, Wang SE, Marino MV, Prasad A, Wang W, He S, Yang K, Liu Q, Wang Z, Li M, Xu S, Wei K, Deng Z, Jia Y, van Ramshorst TME. Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):89-104. doi: 10.21037/hbsn-23-132. Epub 2024 Jan 18. PMID: 38322212
The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS). Abu Hilal M, van Ramshorst TME, Boggi U, Dokmak S, Edwin B, Keck T, Khatkov I, Ahmad J, Al Saati H, Alseidi A, Azagra JS, Björnsson B, Can FM, D'Hondt M, Efanov M, Espin Alvarez F, Esposito A, Ferrari G, Groot Koerkamp B, Gumbs AA, Hogg ME, Huscher CGS, Ielpo B, Ivanecz A, Jang JY, Liu R, Luyer MDP, Menon K, Nakamura M, Piardi T, Saint-Marc O, White S, Yoon YS, Zerbi A, Bassi C, Berrevoet F, Chan C, Coimbra FJ, Conlon KCP, Cook A, Dervenis C, Falconi M, Ferrari C, Frigerio I, Fusai GK, De Oliveira ML, Pinna AD, Primrose JN, Sauvanet A, Serrablo A, Smadi S, Badran A, Baychorov M, Bannone E, van Bodegraven EA, Emmen AMLH, Giani A, de Graaf N, van Hilst J, Jones LR, Levi Sandri GB, Pulvirenti A, Ramera M, Rashidian N, Sahakyan MA, Uijterwijk BA, Zampedri P, Zwart MJW, Alfieri S, Berti S, Butturini G, Di Benedetto F, Ettorre GM, Giuliante F, Jovine E, Memeo R, Portolani N, Ruzzenente A, Salvia R, Siriwardena AK, Besselink MG, Asbun HJ; Collaborators. Ann Surg. 2024 Jan 1;279(1):45-57. doi: 10.1097/SLA.0000000000006006. Epub 2023 Jul 14. PMID: 37450702

Nuklearmedizinische Leitlinien

2025

Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European NeuroendocrineTumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force. Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, Christ E, Lamarca A, Caplin M, Castaño JP, Dromain C, Falconi M, Grozinsky-Glasberg S, Hofland J, Knigge UP, Kos-Kudla B, Krishna BA, Reed NS, Scarpa A, Srirajaskanthan R, Toumpanakis C, Kjaer A, Hicks RJ, Ambrosini V. J Neuroendocrinol. 2025 Feb;37(2):e13479. doi: 10.1111/jne.13479. Epub 2024 Dec 9. PMID: 39653582

2024

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Panzuto F, Albertelli M, De Rimini ML, Rizzo FM, Grana CM, Cives M, Faggiano A, Versari A, Tafuto S, Fazio N, Colao A, Scalorbi F, Ferone D, Cinieri S, Maccauro M. J Endocrinol Invest. 2024 Oct 12. doi: 10.1007/s40618-024-02448-6. Online ahead of print. PMID: 39395114 Review.
Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety. Malandrino P, Feola T, Mikovic N, Cannavale G, Molfetta SD, Altieri B, Mancini C, Ferolla P, Colao A, Faggiano A; NIKE Group. Semin Nucl Med. 2024 Jul;54(4):570-580. doi: 10.1053/j.semnuclmed.2024.05.001. Epub 2024 May 28. PMID: 38811266
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203
Use and perceived utility of [(18) F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. J Neuroendocrinol. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. PMID: 38097193
Incidental 68Ga-DOTATATE uptake in thyroid nodules: Is guideline-directed management still appropriate? Wright K, Fisher JC, Rothberger GD, Prescott JD, Allendorf JD, Patel K, Suh I. Surgery. 2024 Jan;175(1):228-233. doi: 10.1016/j.surg.2023.04.064. Epub 2023 Oct 28. PMID: 38563428

2023

SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. J Nucl Med. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860. PMID: 36725249

2022

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. Clin Nucl Med. 2022 Jun 1;47(6):503-511. doi: 10.1097/RLU.0000000000004182. PMID: 35507433
Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Herrmann K, Giovanella L, Santos A, Gear J, Ozgen Kiratli P, Kurth J, Denis-Bacelar AM, Hustinx R, Patt M, Wahl RL, Paez D, Giammarile F, Jadvar H, Pandit-Taskar N, Ghesani M, Kunikowska J. J Nucl Med. 2022 Dec;63(12):1836-1843. doi: 10.2967/jnumed.122.264321. Epub 2022 Apr 21. PMID: 35450957

2020

NANETS/SNMMIConsensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911. PMID: 32015164

2019

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607. PMID: 31263080

2018

[Somatostatin receptor PET/CT (SSTR-PET/CT)]. Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A. Nuklearmedizin. 2018 Feb;57(1):4-17. German. doi: 10.1055/s-0038-1636560. Epub 2018 Feb 21. PMID: 29536494
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. PMID: 29025982; PMCID: PMC6910630

2017

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Aug 30;: PMID: 28547177
[Selective intraarterial radiotherapy (SIRT) of malignant liver tumors]. Müller SP, Ezziddin S, Antoch G, Lauenstein T, Amthauer H, Haug AR, Bockisch A. Nuklearmedizin. 2017;56(5):162-170. German. doi: 10.3413/Nukmed-2017-05-0001. Epub 2018 Jan 4. PMID: 29533422

2015

[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]. Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP. Nuklearmedizin. 2015;54(1):1-11; quiz N2. German. PMID: 25683107

2013

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):584. O'Dorisiol, T M [corrected to O’Dorisio, T M]. PMID: 23389427; PMCID: PMC3622744

2010

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3. PMID: 20596866

Nuklearmedizinische Literatur - PRRT

2025

Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? Kusne Y, Patnaik MM, Halfdanarson TR, Sonbol MB. Endocr Relat Cancer. 2025 May 1:ERC-25-0025. doi: 10.1530/ERC-25-0025. Online ahead of print. PMID: 40446156 Review.

2024

PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J. J Neuroendocrinol. 2024 Sep 7:e13443. doi: 10.1111/jne.13443. Online ahead of print. PMID: 39243213
[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203
Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm. Trikalinos NA, Kim H, Vijayan A, Amurao M, Prasad V.J Neuroendocrinol. 2024 Jun;36(6):e13393. doi: 10.1111/jne.13393. Epub 2024 Apr 15. PMID: 38622851
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Cordero-Hernandez IS, Ross AC, Dasari A, Halperin DM, Chasen B, Yao JC. Endocr Relat Cancer. 2024 Mar 1;31(4):e230203. doi: 10.1530/ERC-23-0203. Print 2024 Apr 1. PMID: 38329269

2023

The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE. Veerman CHAM, Siebinga H, de Vries-Huizing DMV, Tesselaar MET, Hendrikx JJMA, Stokkel MPM, Aalbersberg EA. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1434-1441. doi: 10.1007/s00259-022-06094-z. Epub 2023 Jan 4. PMID: 36598536

2021

(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Chantadisai M, Kulkarni HR, Baum RP. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1390-1398. doi: 10.1007/s00259-020-05127-9. Epub 2020 Nov 27. PMID: 33247328
177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Fröss-Baron K, Garske-Roman U, Welin S, Granberg D, Eriksson B, Khan T, Sandström M, Sundin A. Neuroendocrinology. 2021;111(4):330-343. doi: 10.1159/000506746. Epub 2020 Feb 25. PMID: 32097917

2019

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11. PMID: 31187162

2018

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7. PMID: 29878866

2017

Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709

Lokoregionäre Therapie / Radioembolisation von Lebermetastasen

2025

Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group. Lam M, Salem R, Toskich B, Kappadath SC, Chiesa C, Fowers K, Haste P, Herman JM, Kim E, Leung T, Padia SA, Sangro B, Sze DY, Garin E. Eur J Nucl Med Mol Imaging. 2025 Mar 28. doi: 10.1007/s00259-025-07229-8. Online ahead of print. PMID: 40148510

Lebertransplantation bei NET

2024

Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis. Angelico R, Bonaccorsi Riani E, De Martin E, Parente A, Foguenne M, Sensi B, Rodríguez-Perálvarez ML; Liver Transplant Immunology Special Interest Group of the International Liver Transplant Society (ILTS). Liver Transpl. 2024 Oct 1. doi: 10.1097/LVT.0000000000000499. Epub ahead of print. PMID: 39347698

2023

S2K-Leitlinie Lebertransplantation - AWMF Leitlinienregister
The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors. Citterio D, Coppa J, Sposito C, Busset MDD, Virdis M, Pezzoli I, Mazzaferro V. Curr Treat Options Oncol. 2023 Nov;24(11):1651-1665. doi: 10.1007/s11864-023-01124-w. Epub 2023 Oct 26. PMID: 37882889; PMCID: PMC10643461.

2020

Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Hibi T, Rela M, Eason JD, Line PD, Fung J, Sakamoto S, Selzner N, Man K, Ghobrial RM, Sapisochin G. Transplantation. 2020 Jun;104(6):1131-1135. doi: 10.1097/TP.0000000000003118. PMID: 32217939

NET Papilla Vateri (ampullary region)

2024

Endoscopic management of gastric, duodenal and rectal NETs: Position paper from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED). Panzuto F, Parodi MC, Esposito G, Massironi S, Fantin A, Cannizzaro R, Milione M, De Angelis CG, Annibale B.Dig Liver Dis. 2024 Apr;56(4):589-600. doi: 10.1016/j.dld.2023.12.015. Epub 2024 Jan 11. PMID: 38216439

2023

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J, Begum N, Sundin A, Falconi M, O'Toole D. J Neuroendocrinol. 2023 Aug;35(8):e13306. doi: 10.1111/jne.13306. Epub 2023 Jul 4. PMID: 37401795
Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study. Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari P, Gulla A, Heise C, Regner S, Gaujoux S; Pancreas 2000 Research Group.Neuroendocrinology. 2023;113(10):1024-1034. doi: 10.1159/000531712. Epub 2023 Jun 27. PMID: 3736918

2022

Survival comparison between endoscopic and surgical resection for non-ampullary duodenal neuroendocrine tumor (1-2 cm). Xie J, Zhang Y, He M, Liu X, Xie P, Pang Y.Sci Rep. 2022 Sep 12;12(1):15339. doi: 10.1038/s41598-022-19725-0. PMID: 36097200
Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. Vanoli A, Grami O, Klersy C, Milanetto AC, Albarello L, Fassan M, Luchini C, Grillo F, Spaggiari P, Inzani F, Uccella S, Parente P, Nappo G, Mattiolo P, Milione M, Pietrabissa A, Cobianchi L, Schiavo Lena M, Partelli S, Di Sabatino A, Sempoux C, Capella C, Pasquali C, Doglioni C, Sessa F, Scarpa A, Rindi G, Paulli M, Zerbi A, Falconi M, Solcia E, La Rosa S.Endocr Pathol. 2022 Jun;33(2):274-288. doi: 10.1007/s12022-022-09720-6. Epub 2022 May 13. PMID: 35553369

Insulinom

2025

Comparative efficacy of systemic therapies in malignant insulinoma. Koch R, McGarrah PW, Vella A, Shah P, Hobday TJ, Sonbol MB, Starr J, Eiring R, McKenzie TJ, Sada A, Starlinger P, Gudmundsdottir H, Halfdanarson TR. Endocr Relat Cancer. 2025 May 1:ERC-25-0091. doi: 10.1530/ERC-25-0091. Online ahead of print. PMID: 40439997

2024

Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT. Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, Brouwers AH, Velikyan I, Waser B, Kauhanen S, Solin O, Marciniak C, Eriksson B, Reubi JC, Aveline C, Wild D, Pattou F, Talbot JN, Hofland J, Sundin A, Nuutila P, Hermans J, Gotthardt M.J Nucl Med. 2024 Oct 17:jnumed.124.268158. doi: 10.2967/jnumed.124.268158. Online ahead of print. PMID: 39419553
Genetic disorders and insulinoma/glucagonoma. Marini F, Giusti F, Brandi ML.Endocr Relat Cancer. 2024 Apr 16;31(5):e230245. doi: 10.1530/ERC-23-0245. Print 2024 May 1. PMID: 38552306
Approach to the Patient: Insulinoma. Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW.J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118. doi: 10.1210/clinem/dgad641. PMID: 37925662
Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma: a state of the art review. Dhar J, Samanta J, Nabi Z, Aggarwal M, Facciorusso A, Conti Bellocchi MC, Crinò SF.Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):37-53. doi: 10.1080/17474124.2024.2321938. Epub 2024 Mar 4. PMID: 38383965

2023

Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Crinò SF, Napoleon B, Facciorusso A, Lakhtakia S, Borbath I, Caillol F, Do-Cong Pham K, Rizzatti G, Forti E, Palazzo L, Belle A, Vilmann P, van Laethem JL, Mohamadnejad M, Godat S, Hindryckx P, Benson A, Tacelli M, De Nucci G, Binda C, Kovacevic B, Jacob H, Partelli S, Falconi M, Salvia R, Landoni L; ERASING study collaborators; Larghi A.Clin Gastroenterol Hepatol. 2023 Oct;21(11):2834-2843.e2. doi: 10.1016/j.cgh.2023.02.022. Epub 2023 Mar 4. PMID: 36871765
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK.J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111/jne.13318. Epub 2023 Aug 14. PMID: 37578384
[Is endosonography-guided radiofrequency ablation of insulinoma a reasonable alternative to surgery?]. Wiese D, Bartsch DK.Chirurgie (Heidelb). 2023 Jun;94(6):550-551. doi: 10.1007/s00104-023-01883-0. Epub 2023 May 4. PMID: 37140658

Gastrinom / ZES

2024

Management of Pancreatic Neuroendocrine Tumors: Surgical Strategies and Controversies. Perry RR, Feliberti EC, Hughes MS.Endocr Pract. 2024 Oct;30(10):908-916. doi: 10.1016/j.eprac.2024.07.010. Epub 2024 Jul 18. PMID: 39032831
[Individualized approach for MEN1-associated duodenopancreatic neuroendocrine neoplasms]. Manoharan J, Albers MB, Bartsch DK.Chirurgie (Heidelb). 2024 Mar;95(3):207-215. doi: 10.1007/s00104-023-01994-8. Epub 2024 Jan 5. PMID: 38180518

2023

How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors? Imamura M, Komoto I, Taki Y.Surg Today. 2023 Dec;53(12):1325-1334. doi: 10.1007/s00595-022-02627-z. Epub 2022 Dec 7. PMID: 36473964
Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries. Tonelli F, Marini F, Giusti F, Iantomasi T, Giudici F, Brandi ML.Cancers (Basel). 2023 Oct 10;15(20):4919. doi: 10.3390/cancers15204919. PMID: 37894286
[Prognostic and surgical technique factors for recurrence after resection of a sporadic gastrinoma]. Wiese D, Bartsch DK.Chirurgie (Heidelb). 2023 Aug;94(8):731-732. doi: 10.1007/s00104-023-01928-4. Epub 2023 Jun 30. PMID: 37389640
All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update. Chatzipanagiotou O, Schizas D, Vailas M, Tsoli M, Sakarellos P, Sotiropoulou M, Papalambros A, Felekouras E.J Neuroendocrinol. 2023 Apr;35(4):e13267. doi: 10.1111/jne.13267. Epub 2023 Apr 11. PMID: 37042078
Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES. Ito T, Ramos-Alvarez I, Jensen RT.Cancers (Basel). 2023 Feb 21;15(5):1377. doi: 10.3390/cancers15051377. PMID: 36900170

2022

Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. Kong W, Albers MB, Manoharan J, Goebel JN, Kann PH, Jesinghaus M, Bartsch DK.Cancers (Basel). 2022 Apr 11;14(8):1928. doi: 10.3390/cancers14081928. PMID: 35454834

2021

Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, Massironi S.World J Gastroenterol. 2021 Sep 21;27(35):5890-5907. doi: 10.3748/wjg.v27.i35.5890. PMID: 34629807

NEN Head and Neck

2025

Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Resteghini C, Baujat B, Bossi P, Franchi A, de Gabory L, Halamkova J, Haubner F, Hardillo JAU, Hermsen MA, Iacovelli NA, Maroldi R, Mattheis S, Moya-Plana A, Nicolai P, Orlandi E, Thariat J, Trama A, van den Brekel MWM, van Herpen CML, Verillaud B, Kinloch E, Licitra L, Even C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2025 Feb;10(2):104121. doi: 10.1016/j.esmoop.2024.104121. Epub 2025 Feb 6. PMID: 39986703

2024

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, Pavel M, Thariat J, van Velthuysen MF, Herman P, Dromain C, Baudin E, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2024 Oct;9(10):103664. doi: 10.1016/j.esmoop.2024.103664. Epub 2024 Oct 1. PMID: 39461777

NEN des gynäkologischen Trakts

2024

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, Pavel M, Thariat J, van Velthuysen MF, Herman P, Dromain C, Baudin E, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2024 Oct;9(10):103664. doi: 10.1016/j.esmoop.2024.103664. Epub 2024 Oct 1. PMID: 39461777

2023

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Endocr Relat Cancer. 2023 Jul 11;30(8):e220206. doi: 10.1530/ERC-22-0206. PMID: 37184955; PMCID: PMC10388681

2021

Neuroendocrine tumors of the gynecologic tract update. Winer I, Kim C, Gehrig P. Gynecol Oncol. 2021 Jul;162(1):210-219. doi: 10.1016/j.ygyno.2021.04.039. Epub 2021 May 20. PMID: 34023130

NEN der Prostata / NEPC

2024

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME. Epigenomics. 2024;16(17):1129-1132. doi: 10.1080/17501911.2024.2391729. Epub 2024 Sep 3. PMID: 39225130
Promising therapy for neuroendocrine prostate cancer: current status and future directions. Fei X, Xue JW, Wu JZ, Yang CY, Wang KJ, Ma Q. Ther Adv Med Oncol. 2024 Aug 8;16:17588359241269676. doi: 10.1177/17588359241269676. PMID: 39131727
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. JU Open Plus. 2024 Apr;2(4):e00032. doi: 10.1097/ju9.0000000000000138. Epub 2024 Apr 15. PMID: 38774467
The Current Therapeutic Landscape for Metastatic Prostate Cancer. Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G. Pharmaceuticals (Basel). 2024 Mar 8;17(3):351. doi: 10.3390/ph17030351. PMID: 38543137 Free PMC article. Review
Diagnosis and management of neuroendocrine prostate cancer. de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Prostate. 2024 Jan 3. doi: 10.1002/pros.24664. Epub ahead of print. PMID: 38173302

2023

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, Miyamoto H. Anticancer Res. 2023 Sep;43(9):3841-3847. doi: 10.21873/anticanres.16571. PMID: 37648316 Review.

2019

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. PMID: 30713600; PMCID: PMC6343754

Karzinoide Lunge & Thymus

2025

Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks. Fodil-Cherif S, Hadoux J, Mercier O, Benitez JC, Durand A, Lasolle H, Perrier M, Jannin A, Laboureau S, Le Bras M, Chabre O, Gaujoux S, Rouiller LG, Hentic O, Du Boullay H, Haissaguerre M, Kinn H, Lecomte T, Goudet P, Girard N, Scoazec JY, Besse B, Faron M, Baudin E. J Thorac Oncol. 2025 May 4:S1556-0864(25)00702-6. doi: 10.1016/j.jtho.2025.04.013. Online ahead of print. PMID: 40328381
A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A. BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3. PMID: 40186126
A Review for the Clinician: Classifications, Genetics, and Treatment for Neuroendocrine Neoplasms of the Thymus (Thymic Carcinoids). Lang M, Anamaterou C, Mohr I, Černá M, Röhrich M, Tjaden C. Neuroendocrinology. 2025 Mar 11:1-12. doi: 10.1159/000544982. Online ahead of print. PMID: 40068632 Review.
Raising the bar: evaluating quality and consistency in clinical guidelines for surgical management of pulmonary carcinoid. Bertolaccini L, Bardoni C, Caffarena G, Chiari M, Diotti C, Mazzella A, Benini L, Spada F, Corso G, Pisa E, Casiraghi M, Fazio N, Spaggiari L. Eur J Cancer Prev. 2025 Jan 7. doi: 10.1097/CEJ.0000000000000949. Online ahead of print. PMID: 39786538

2024

Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure? Heijboer FWJ, Mulders TA, van Straten M, Moonen L, Speel EM, von der Thüsen JH, Derks JL, Dingemans AC. Lung Cancer. 2024 Dec;198:108030. doi: 10.1016/j.lungcan.2024.108030. Epub 2024 Nov 17. PMID: 3955697
Recurrence Rates and Patterns after Radical Resection of Lung Carcinoids. Askildsen E, Soldath P, Langer SW, Andreassen M, Knigge U, Petersen RH. Cancers (Basel). 2024 Aug 27;16(17):2978. doi: 10.3390/cancers16172978. PMID: 39272839
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force. Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, Foll M, Dromain C, Reed NS, Caplin M, Capdevila J, Falkerby J, Faggiano A, Frilling A, Grande E, Hicks RJ, Kasajima A, Kos-Kudla B, Krishna BA, Lim E, Rinke A, Singh S, Thirlwell C, Volante M, Walter T. J Neuroendocrinol. 2024 Aug;36(8):e13412. doi: 10.1111/jne.13412. Epub 2024 May 16. PMID: 38754956
Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety. Malandrino P, Feola T, Mikovic N, Cannavale G, Molfetta SD, Altieri B, Mancini C, Ferolla P, Colao A, Faggiano A; NIKE Group. Semin Nucl Med. 2024 Jul;54(4):570-580. doi: 10.1053/j.semnuclmed.2024.05.001. Epub 2024 May 28. PMID: 38811266

2023

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Dam G, Grønbæk H, Sundlöv A, Botling J, Sundin A, Petersen RH, Welin S, Evensen ET, Sorbye H, Tabaksblat E, Arveschoug AK, Mortensen J, Kjaer A, Knigge U, Tiensuu Janson E, Langer SW. Acta Oncol. 2023 May;62(5):431-437. doi: 10.1080/0284186X.2023.2212411. Epub 2023 May 16. PMID: 37194281

2021

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Erratum in: Ann Oncol. 2021 Nov;32(11):1453-1455. PMID: 33482246

2020

Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. J Thorac Oncol. 2020 Oct;15(10):1577-1598. doi: 10.1016/j.jtho.2020.06.021. Epub 2020 Jul 11. PMID: 32663527

Carcinoid Heart Syndrome / Hedinger Syndrom

2023

Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. Das S, Stockton SS, Hassan SA. Oncologist. 2023 Jul 5;28(7):575-583. doi: 10.1093/oncolo/oyad126. PMID: 37209415
Carcinoid heart disease in patients with midgut neuroendocrine tumours. Delhomme C, Walter T, Arangalage D, Suc G, Hentic O, Cachier A, Alkhoder S, François L, Lombard-Bohas C, Iung B, Ruszniewski P, de Mestier L. J Neuroendocrinol. 2023 Apr;35(4):e13262. doi: 10.1111/jne.13262. Epub 2023 Apr 2. PMID: 37005217

2022

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. doi: 10.1093/eurheartj/ehad196. PMID: 36017568
European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Albåge A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111/jne.13146. Epub 2022 May 25. PMID: 35613326
Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force). Hofland J, Lamarca A, Steeds R, Toumpanakis C, Srirajaskanthan R, Riechelmann R, Panzuto F, Frilling A, Denecke T, Christ E, Grozinsky-Glasberg S, Davar J; ENETS Carcinoid Heart Disease Task Force. J Neuroendocrinol. 2022 Mar;34(3):e13060. doi: 10.1111/jne.13060. Epub 2021 Nov 26. PMID: 34825753

Multiple Endokrine Neoplasie Typ 1

2025

Highlights from the AACE Consensus Statement on Multiple EndocrineNeoplasia Type 1: A Patient's Perspective. Keller J. Endocr Pract. 2025 Apr;31(4):554-555. doi: 10.1016/j.eprac.2025.02.010. PMID: 40246402
American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1. Del Rivero J, Gangi A, Annes JP, Jasim S, Keller J, Lundholm MD, Silverstein JM, Vaghaiwalla TM, Wermers RA. Endocr Pract. 2025 Mar 26:S1530-891X(25)00038-2. doi: 10.1016/j.eprac.2025.02.001. Online ahead of print. PMID: 40232217

2023

French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d'étude des Tumeurs Endocrines / Association Française de Chirurgie Endocrinienne / REseau NAtional de prise en charge des Tumeurs ENdocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1. Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L, Caiazzo R, Cardot-Bauters C, Castinetti F, Chanson P, Cuny T, Dansin E, Gaujoux S, Giraud S, Groussin L, Bras ML, Lifante JC, Mathonnet M, de Mestier L, Mirallié E, Pattou F, Romanet P, Sebag F, Tresallet C, Vezzosi D, Walter T, Tabarin A. Ann Endocrinol (Paris). 2023 Sep 20:S0003-4266(23)00707-2. doi: 10.1016/j.ando.2023.09.003. Online ahead of print. PMID: 37739121 Review. No abstract available.

2021

Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, Goudet P, Halfdanarson TR, Ito T, Jensen RT, Larghi A, Lee L, Öberg K, Pavel M, Perren A, Sadowski SM, Tonelli F, Triponez F, Valk GD, O'Toole D, Scott-Coombes D, Thakker RV, Thompson GB, Treglia G, Wiedenmann B. Neuroendocrinology. 2021;111(7):609-630. doi: 10.1159/000511791. Epub 2020 Sep 24. PMID: 32971521

2012

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML; Endocrine Society. J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011. doi: 10.1210/jc.2012-1230. Epub 2012 Jun 20. PMID: 22723327

Von-Hippel-Lindau-Sydrom

2025

Update on Surveillance in Von Hippel-Lindau Disease. Rednam SP, Becktell KD, Villani A, Brodeur GM, States LJ, Doria AS, Kamihara J, Schneider KW, Voss SD, Widjaja E, Zelley K, Nakano Y, Pajtler KW, Achatz MI, Malkin D, Diller LR, Gallinger B, Tamura C, Wasserman JD. Clin Cancer Res. 2025 Apr 15. doi: 10.1158/1078-0432.CCR-24-3525. Online ahead of print. PMID: 40232410

2023

Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J; International VHL Surveillance Guidelines Consortium. Cancer. 2023 Jun 19. doi: 10.1002/cncr.34896. Epub ahead of print. PMID: 37337409

2022

Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A; Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Cancer. 2022 Feb 1;128(3):435-446. doi: 10.1002/cncr.33978. Epub 2021 Nov 4. PMID: 34735022

2021

Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement. Huntoon K, Shepard MJ, Lukas RV, McCutcheon IE, Daniels AB, Asthagiri AR. J Neurosurg. 2021 Oct 1;136(6):1511-1516. doi: 10.3171/2021.3.JNS204203. PMID: 34598132

2013

Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Binderup ML, Bisgaard ML, Harbud V, Møller HU, Gimsing S, Friis-Hansen L, Hansen Tv, Bagi P, Knigge U, Kosteljanetz M, Bøgeskov L, Thomsen C, Gerdes AM, Ousager LB, Sunde L; Danish vHL Coordination Group. Dan Med J. 2013 Dec;60(12):B4763. PMID: 24355456

Neurofibromatose Typ 1

2023

ERN GENTURIS NF1 Tumour Management Guideline Group. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, Röhl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R. EClinicalMedicine. 2023 Jan 13;56:101818. doi: 10.1016/j.eclinm.2022.101818. PMID: 36684394; PMCID: PMC9845795

2022

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Merker VL, Knight P, Radtke HB, Yohay K, Ullrich NJ, Plotkin SR, Jordan JT. Orphanet J Rare Dis. 2022 Feb 10;17(1):44. doi: 10.1186/s13023-022-02196-x. PMID: 35144646; PMCID: PMC8832755

2021

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Evans DG, Plotkin SR. Genet Med. 2021 Aug;23(8):1506-1513. doi: 10.1038/s41436-021-01170-5. Epub 2021 May 19. PMID: 34012067; PMCID: PMC8354850

2020

Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P; NF France Network. Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3. PMID: 32014052; PMCID: PMC6998847

2018

Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Genet Med. 2018 Jul;20(7):671-682. doi: 10.1038/gim.2018.28. Epub 2018 Apr 26. PMID: 30006586

Appendix goblet cell Adenokarzinom

2024

The Optimal Approach to Surgical Management of Goblet Cell Carcinoid of the Appendix: A Systematic Review. Salama MM, O'Neill MA, Ryan ÉJ, O'Sullivan NJ, Nugent TS, Temperley HC, Mehigan BJ, Larkin JO, Gallagher D, O'Kane G, McCormick PH, Kelly ME. Diagnostics (Basel). 2024 Aug 14;14(16):1773. doi: 10.3390/diagnostics14161773. PMID: 39202258

2022

Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry. Palmer K, Weerasuriya S, Chandrakumaran K, Rous B, White BE, Paisey S, Srirajaskanthan R, Ramage JK. Front Oncol. 2022 Jul 12;12:915028. doi: 10.3389/fonc.2022.915028. PMID: 35903705

2021

Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ; PSOGI. Eur J Surg Oncol. 2021 Jan;47(1):11-35. doi: 10.1016/j.ejso.2020.02.012. Epub 2020 Feb 28. PMID: 32199769

2020

The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Chicago Consensus Working Group. Ann Surg Oncol. 2020 Jun;27(6):1788-1792. doi: 10.1245/s10434-020-08321-z. Epub 2020 Apr 13. PMID: 32285274

Appendix Neuroendokrine Tumoren

2024

Lymph node metastases are more frequent in paediatric appendiceal NET ≥1.5 cm but without impact on outcome - Data from the German MET studies. Kuhlen M, Kunstreich M, Pape UF, Seitz G, Lessel L, Vokuhl C, Frühwald MC, Vorwerk P, Redlich A. Eur J Surg Oncol. 2024 Apr;50(4):108051. doi: 10.1016/j.ejso.2024.108051. Epub 2024 Feb 27. PMID: 38430702

2023

Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study. Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, Brcic I, Brunner M, Cadiot G, Camara M, Christ E, Clerici T, Clift AK, Clouston H, Cobianchi L, Ćwikła JB, Daskalakis K, Frilling A, Garcia-Carbonero R, Grozinsky-Glasberg S, Hernando J, Hervieu V, Hofland J, Holmager P, Inzani F, Jann H, Jimenez-Fonseca P, Kaçmaz E, Kaemmerer D, Kaltsas G, Klimacek B, Knigge U, Kolasińska-Ćwikła A, Kolb W, Kos-Kudła B, Kunze CA, Landolfi S, La Rosa S, López CL, Lorenz K, Matter M, Mazal P, Mestre-Alagarda C, Del Burgo PM, van Dijkum EJMN, Oleinikov K, Orci LA, Panzuto F, Pavel M, Perrier M, Reims HM, Rindi G, Rinke A, Rinzivillo M, Sagaert X, Satiroglu I, Selberherr A, Siebenhüner AR, Tesselaar MET, Thalhammer MJ, Thiis-Evensen E, Toumpanakis C, Vandamme T, van den Berg JG, Vanoli A, van Velthuysen MF, Verslype C, Vorburger SA, Lugli A, Ramage J, Zwahlen M, Perren A, Kaderli RM. Lancet Oncol. 2023 Feb;24(2):187-194. doi: 10.1016/S1470-2045(22)00750-1. Epub 2023 Jan 11. PMID: 36640790

Pediatric Rare Tumors (EXPeRT)

2025

Appendiceal neuroendocrine tumors in children and adolescents: The European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) diagnostic and therapeutic recommendations. Virgone C, Roganovic J, Rindi G, Kuhlen M, Jamsek J, Panagopoulou P, Bajciova V, Ben-Ami T, Raphael MF, Seitz G, Dall'Igna P, Terwisscha van Scheltinga SCEJ, Dierselhuis MP, Gorter RR, Bachiri S, Pape UF, Guérin F, Brecht IB, Fresneau B, Orbach D, Redlich A. Surgery. 2025 May 31;184:109451. doi: 10.1016/j.surg.2025.109451. Online ahead of print. PMID: 40450811

Pheochromocytoma | Paraganglioma Guidelines

2025

Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines. Pamporaki C, Casey RT. Best Pract Res Clin Endocrinol Metab. 2025 Jan;39(1):101957. doi: 10.1016/j.beem.2024.101957. Epub 2024 Nov 14. PMID: 39551655

2024

Head and neck paragangliomas: Recent advances in translational and clinical research and guidelines for patient care. Richter S, Constantinescu G, Fancello G, Paties CT, Mariani-Costantini R, Sanna M. Best Pract Res Clin Endocrinol Metab. 2024 Dec;38(6):101951. doi: 10.1016/j.beem.2024.101951. Epub 2024 Sep 11. PMID: 39294042
Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients. Lussey-Lepoutre C, Pacak K, Grossman A, Taieb D, Amar L. Best Pract Res Clin Endocrinol Metab. 2024 Sep 7:101938. doi: 10.1016/j.beem.2024.101938. Online ahead of print. PMID: 39271377
International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Casey RT, Hendriks E, Deal C, Waguespack SG, Wiegering V, Redlich A, Akker S, Prasad R, Fassnacht M, Clifton-Bligh R, Amar L, Bornstein S, Canu L, Charmandari E, Chrisoulidou A, Freixes MC, de Krijger R, de Sanctis L, Fojo A, Ghia AJ, Huebner A, Kosmoliaptsis V, Kuhlen M, Raffaelli M, Lussey-Lepoutre C, Marks SD, Nilubol N, Parasiliti-Caprino M, Timmers HHJLM, Zietlow AL, Robledo M, Gimenez-Roqueplo AP, Grossman AB, Taïeb D, Maher ER, Lenders JWM, Eisenhofer G, Jimenez C, Pacak K, Pamporaki C. Nat Rev Endocrinol. 2024 Aug 15. doi: 10.1038/s41574-024-01024-5. Online ahead of print. PMID: 39147856

2023

Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Taïeb D, Wanna GB, Ahmad M, Lussey-Lepoutre C, Perrier ND, Nölting S, Amar L, Timmers HJLM, Schwam ZG, Estrera AL, Lim M, Pollom EL, Vitzthum L, Bourdeau I, Casey RT, Castinetti F, Clifton-Bligh R, Corssmit EPM, de Krijger RR, Del Rivero J, Eisenhofer G, Ghayee HK, Gimenez-Roqueplo AP, Grossman A, Imperiale A, Jansen JC, Jha A, Kerstens MN, Kunst HPM, Liu JK, Maher ER, Marchioni D, Mercado-Asis LB, Mete O, Naruse M, Nilubol N, Pandit-Taskar N, Sebag F, Tanabe A, Widimsky J, Meuter L, Lenders JWM, Pacak K. Lancet Diabetes Endocrinol. 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31. PMID: 37011647; PMCID: PMC10182476

2022

Personalized Management of Pheochromocytoma and Paraganglioma. Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019. Erratum in: Endocr Rev. 2021 Dec 14;: Erratum in: Endocr Rev. 2021 Dec 14;: PMID: 34147030; PMCID: PMC8905338
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Mete, O., Asa, S.L., Gill, A.J. et al. Endocr Pathol 33, 90–114 (2022). https://doi.org/10.1007/s12022-022-09704-6

2021

International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, Buffet A, Burnichon N, Clifton-Bligh RJ, Dahia PLM, Fassnacht M, Grossman AB, Herman P, Hicks RJ, Januszewicz A, Jimenez C, Kunst HPM, Lewis D, Mannelli M, Naruse M, Robledo M, Taïeb D, Taylor DR, Timmers HJLM, Treglia G, Tufton N, Young WF, Lenders JWM, Gimenez-Roqueplo AP, Lussey-Lepoutre C. Nat Rev Endocrinol. 2021 Jul;17(7):435-444. doi: 10.1038/s41574-021-00492-3. Epub 2021 May 21. PMID: 34021277
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. Pancreas. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792. PMID: 33939658

2019

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29. PMID: 31254038; PMCID: PMC7446938
Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK). Lorenz K, Langer P, Niederle B, Alesina P, Holzer K, Nies C, Musholt T, Goretzki PE, Rayes N, Quinkler M, Waldmann J, Simon D, Trupka A, Ladurner R, Hallfeldt K, Zielke A, Saeger D, Pöppel T, Kukuk G, Hötker A, Schabram P, Schopf S, Dotzenrath C, Riss P, Steinmüller T, Kopp I, Vorländer C, Walz MK, Bartsch DK. Langenbecks Arch Surg. 2019 Jun;404(4):385-401. doi: 10.1007/s00423-019-01768-z. Epub 2019 Apr 1. PMID: 30937523

2016

European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. Eur J Endocrinol. 2016 May;174(5):G1-G10. doi: 10.1530/EJE-16-0033. PMID: 27048283

2014

Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. Erratum in: J Clin Endocrinol Metab. 2023 Apr 13;108(5):e200. PMID: 24893135

Cushing | adrenal Guidelines

2023

Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA. Rowe NE, Kumar R, Schieda N, Siddiqi F, McGregor T, McAlpine K, Violette P, Bathini V, Eng M, Izard J.J Urol. 2023 Oct;210(4):590-599. doi: 10.1097/JU.0000000000003644. Epub 2023 Aug 9. PMID: 37556768
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM.Eur J Endocrinol. 2023 Jul 20;189(1):G1-G42. doi: 10.1093/ejendo/lvad066. PMID: 37318239

2022

American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C, Velázquez-Fernández D, Berber E, Hammer GD, Bancos I, Lee JA, Marko J, Morris-Wiseman LF, Hughes MS, Livhits MJ, Han MA, Smith PW, Wilhelm S, Asa SL, Fahey TJ 3rd, McKenzie TJ, Strong VE, Perrier ND. JAMA Surg. 2022 Oct 1;157(10):870-877. doi: 10.1001/jamasurg.2022.3544. PMID: 35976622

2021

Consensus on diagnosis and management of Cushing's disease: a guideline update. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. PMID: 34687601; PMCID: PMC8743006

2019

Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK). Lorenz K, Langer P, Niederle B, Alesina P, Holzer K, Nies C, Musholt T, Goretzki PE, Rayes N, Quinkler M, Waldmann J, Simon D, Trupka A, Ladurner R, Hallfeldt K, Zielke A, Saeger D, Pöppel T, Kukuk G, Hötker A, Schabram P, Schopf S, Dotzenrath C, Riss P, Steinmüller T, Kopp I, Vorländer C, Walz MK, Bartsch DK. Langenbecks Arch Surg. 2019 Jun;404(4):385-401. doi: 10.1007/s00423-019-01768-z. Epub 2019 Apr 1. PMID: 30937523

2015

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. PMID: 26222757; PMCID: PMC4525003

Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) , der Deutschen Krebsgesellschaft e.V. (DKG) und der Deutschen Krebshilfe.

Supportive Therapie

Psychoonkologie

Palliativmedizin

Leitlinien Komplementärmedizin, Supportive Therapie, Psychoonkologie (AWMF)

Komplementärmedizin

Supportive Medizin

Psychoonkologie

Endoskopisches Management von Neuroendokrinen Neoplasien

2025

AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review. Shah SC, Wang AY, Wallace MB, Hwang JH. Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. PMID: 39718517

2024

Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis. Chen J, Ye J, Zheng X, Chen J. J Gastrointest Surg. 2024 Mar;28(3):301-308. doi: 10.1016/j.gassur.2023.12.016. Epub 2024 Jan 23. PMID: 38445925

2023

Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study. Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari P, Gulla A, Heise C, Regner S, Gaujoux S; Pancreas 2000 Research Group. Neuroendocrinology. 2023;113(10):1024-1034. doi: 10.1159/000531712. Epub 2023 Jun 27. PMID: 37369186

2022

Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Deprez PH, Moons LMG, OʼToole D, Gincul R, Seicean A, Pimentel-Nunes P, Fernández-Esparrach G, Polkowski M, Vieth M, Borbath I, Moreels TG, Nieveen van Dijkum E, Blay JY, van Hooft JE. Endoscopy. 2022 Apr;54(4):412-429. doi: 10.1055/a-1751-5742. Epub 2022 Feb 18. PMID: 35180797

Leitlinien Ernährung bei neuroendokrinen Neoplasien

2025

Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group. Vitale G, Gaudenzi G, Oldani M, Pandozzi C, Filice A, Jaafar S, Barrea L, Colao A, Faggiano A; Nike Group. Rev Endocr Metab Disord. 2025 Apr;26(2):161-174. doi: 10.1007/s11154-024-09937-2. Epub 2024 Dec 9. PMID: 39653986

Covid-19 bei Patient- en/innen mit NEN

2021

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Eur J Cancer. 2021 Feb;144:200-214. doi: 10.1016/j.ejca.2020.11.037. Epub 2020 Dec 25. PMID: 33370645; PMCID: PMC7836777

2020

North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. Pancreas. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561. PMID: 32433264; PMCID: PMC7253037
Internationale Fachgesellschaften

European Neuroendocrine Tumor Society (ENETS)

European Society of Endocrine Surgeons (ESES)

European Society for Medical Oncology (ESMO)

National Comprehensive Cancer Network (NCCN)

North American Neuroendocrine Tumor Society (NANETS)

American Society of Clinical Oncology (ASCO)
Nationale Fachgesellschaften

DGVS

DGAV

DGE

DGHO

DKG

AIO

DGN

DGP

Leitlinien, Literatur und Fachgesellschaften

Leitlinien internationaler Fachgesellschaften

ENETS - Consensus Report 2025

ENETS - Guidance Paper 2024

ENETS - Guidance Paper 2023

ENETS-Empfehlungen – Standardized Synoptic Reporting 2021/2022

ENETS - Standards of Care 2017

ENETS - Guidelines 2016

2024

2024

2021

2020

2023

2020

2018

2017

2013

2025

2023

Leitlinien nationaler Fachgesellschaften

2018

2023

2021

2014

2010

2022

2018

2014

2011

2022

2020

2024

2022

2021

Themenspezifische Literatur / Leitlinien / Reviews

2024

2024

2022

2025

2024

Somatostatinanaloga

Telotristat

177Lu-DOTA-TATE

Everolimus

Sunitinib

Cabozantinib

Surufatinib

Bevacizumab

2024

2023

2022

2024

2024

2025

2024

2023

2022

2020

2019

2018

2017

2015

2013

2010

2025

2024

2023

2021

2019

2018

2017

2025

2024

2023

2020

2024

2023

2022

2025

2024